·SEC EDGARLow
Plott Ronald Todd purchased $15K of PHIO
Plott Ronald Todd purchased 18,300 shares of Phio Pharmaceuticals Corp. (PHIO) at $0.83 on 2026-11-09.
StockNASDAQ · US · USDHealthcare · Biotechnology
$PHIO
Phio Pharmaceuticals Corp.
Phio Pharmaceuticals is a clinical-stage biopharmaceutical company developing cancer therapeutics based on its proprietary INTASYL small interfering RNA gene-silencing technology. Its compounds are designed to silence proteins tumors use to evade the immune system and make immune cells more effective at killing tumor cells. Phio operates as a single segment and focuses on immuno-oncology. Its lead candidate, PH-762, is being evaluated in a U.S. Phase 1b trial for cutaneous squamous cell carcinoma, melanoma and Merkel cell carcinoma. PH-894, designed to silence BRD4, has completed IND-enabling studies, with its IND submission deferred. Phio develops product candidates and relies on contract manufacturers to produce drug substances and products for nonclinical studies and clinical trials. It operates as a remote business and maintains shared office space in King of Prussia, Pennsylvania.
AlphAI earnings readThird Quarter 2026 · NOV 5Phio Pharmaceuticals Reports Third Quarter 2026 Financial Results and Business Update as it Advances PH-762 Toward Phase 2b Study InitiationVerdict: mixedRead →
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
Price · $PHIOvia TradingView
AI sentiment · 7d9 articles
- Bullish
- 4
- Neutral
- 3
- Bearish
- 2
Insider · 30dAll trades →
- Buys
- $36K 2 txs
- Sells
- — 0 txs
Bitterman Robert J1× · $21K
10b5-1 share of filings0%
Top stories · $PHIOMore →
·SEC EDGAR
Bitterman Robert J purchased $20K of PHIO
Bitterman Robert J (Chairman, Pres. & CEO) purchased 25,000 shares of Phio Pharmaceuticals Corp. (PHIO) at $0.82 on 2026-11-09.
·timminspress.com
Phio Pharmaceuticals Announces e-Presentation at American Society for Dermatologic Surgery (ASDS) Annual Meeting
Phio Pharmaceuticals (PHIO) presented Phase 1b trial data for its cancer treatment PH-762 at the ASDS Annual Meeting. The study suggested PH-762 is well-tolerated and may offer a tissue-sparing neoadjuvant therapy for cutaneous carcinomas. A Phase 2b study is planned for 2027. According to the company, PH-762 could improve patient outcomes by shrinking tumors before surgery.
PHIO sentiment & insider activity
Over the past 7 days, AlphAI's AI scored 9 news stories mentioning PHIO (Phio Pharmaceuticals Corp.). Coverage has skewed bullish: 4 bullish, 3 neutral, and 2 bearish.
Recent PHIO coverage spans financial news, insider activity and corporate actions.
In the last 30 days, PHIO insiders filed 2 SEC Form 4 transactions — 2 purchases ($36K) and no sales. The most active reporter was Bitterman Robert J, Chairman, Pres. & CEO, with 1 filing.
What's driving PHIO
The insider purchase suggests confidence from a board member, likely creating modest buying pressure.
Small insider purchase may signal confidence but unlikely to move price materially.
Positive early‑stage data may lift investor sentiment and drive short‑term upside.
Positive early‑stage data may boost investor confidence in PHIO's pipeline.
Milestone reduces development risk and may lift the stock.
AlphAI scores every news story that mentions PHIO with an AI model for sentiment and relevance, and aggregates insider trades from Phio Pharmaceuticals Corp.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
News on $PHIO
Score
Plott Ronald Todd purchased $15K of PHIO
Plott Ronald Todd purchased 18,300 shares of Phio Pharmaceuticals Corp. (PHIO) at $0.83 on 2026-11-09.
Bitterman Robert J purchased $20K of PHIO
Bitterman Robert J (Chairman, Pres. & CEO) purchased 25,000 shares of Phio Pharmaceuticals Corp. (PHIO) at $0.82 on 2026-11-09.
Phio Pharmaceuticals Announces e-Presentation at American Society for Dermatologic Surgery (ASDS) Annual Meeting
Phio Pharmaceuticals (PHIO) presented Phase 1b trial data for its cancer treatment PH-762 at the ASDS Annual Meeting. The study suggested PH-762 is well-tolerated and may offer a tissue-sparing neoadjuvant therapy for cutaneous carcinomas. A Phase 2b study is planned for 2027. According to the company, PH-762 could improve patient outcomes by shrinking tumors before surgery.
Study results suggest a skin cancer treatment may spare tissue before surgery
Phio Pharmaceuticals (PHIO) announced positive Phase 1b trial results for its skin cancer treatment PH-762, to be presented at the SITC meeting. The data suggests PH-762 may shrink tumors before surgery with a favorable safety profile, according to the company. A Phase 2b study is planned for 2027.
Phio Pharmaceuticals Reports Third Quarter 2026 Financial Results and Business Update as It Advances PH-762 Toward Phase 2b Study Initiation
Phio Pharmaceuticals (PHIO) reported Q3 2026 results, advancing PH-762 toward Phase 2b study. Key milestones include FDA submission, commercial-scale manufacturing, and patent achievements. The company expects FDA feedback by November 2026 and Phase 2b initiation in Q1 2027. Financial details include cash position, R&D, and G&A expenses, with net loss reported.
Phio Pharmaceuticals Announces Successful Completion of First Commercial-Scale cGMP Batch of PH-762 Drug Substance
Phio Pharmaceuticals Corp. (PHIO) filed an SEC Form 8-K — Other Events. Exhibit 99.1 Phio Pharmaceuticals Announces Successful Completion of First Commercial-Scale cGMP Batch of PH-762 Drug Substance Critical Manufacturing Milestone Supports Supply Chain Readiness and Planned Phase 2b Clinical Trial Initiation in First Quarter 2027 KING OF PRUSSIA, P
A cancer drug's first production-scale batch is complete; a clinical study is planned for early 2027.
Phio Pharmaceuticals (PHIO) announced the successful production of its first commercial-scale batch of PH-762, a cancer drug. The batch meets quality standards and will be used in a planned Phase 2b clinical trial set to begin in Q1 2027. The company's CEO highlighted this as a significant milestone, reducing development risks and supporting future clinical and regulatory steps.
Plott Ronald Todd purchased $10K of PHIO
Plott Ronald Todd purchased 10,000 shares of Phio Pharmaceuticals Corp. (PHIO) at an average of $1.04 ($1.03–$1.04) across 2 trades over 2026-09-28 to 2026-09-29.
Phio Pharmaceuticals Corp. (PHIO): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Phio Pharmaceuticals Corp. (PHIO) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Phio Pharmaceuticals Corp. (the “Company”) held its 2026 Annual Meeting of Stockholders via live webcast (the “Annual Meet
BRADFORD PATRICIA A purchased $7K of PHIO
BRADFORD PATRICIA A purchased 6,500 shares of Phio Pharmaceuticals Corp. (PHIO) at $1.01 on 2026-09-24.